Individual Patient Compassionate Use of Mirdametinib

SpringWorks Therapeutics, Inc.

Overview

This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.

Study Type

EXPANDED_ACCESS

Conditions

Neurofibromatosis Type 1-Associated Plexiform Neurofibromas Histiocytic Neoplasm Other MAP-K Pathway Driven Diseases

Interventions

Mirdametinib (MEK Inhibitor)DRUG

Patients will receive oral mirdametinib.

Eligibility

Sex: ALLMin age: 2 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient has a serious, debilitating or life-threatening medical condition that cannot be treated satisfactorily with an authorized medicinal product or other available standard treatment options, or all other treatment options have been exhausted. * Patient does not qualify to participate in an ongoing clinical trial.

Central Contacts

SpringWorks Medical Information

CONTACT

(888) 400-7989 medinfo@springworkstx.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.